New drug combo tested in fight against Tough-to-Treat cancers
Disease control
Ongoing
This early-stage study is testing the safety and best dose of a new drug, ELVN-002, when given with standard treatments for advanced HER2-positive cancers. It will involve about 275 adults with cancers like breast, colorectal, or gastric cancer that have spread or returned after …
Phase: PHASE1 • Sponsor: Enliven Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC